The primary objective of the study was to evaluate the safety and tolerability of intravenous dosing of PulmoStem in patients with severe lower respiratory infections such as Covid-19, influenza A, and RS virus. The study also included secondary and exploratory endpoints related to lung regeneration, biomarkers of inflammatory response, and other clinical endpoints. The study was an adaptive and dose-escalating study that included 6 hospitalized patients with Covid-19 or other respiratory tract infections and was conducted at a clinic in Sweden.

No dose-limiting toxicity were noted in the first or second dose cohorts, which was the primary endpoint of the study. In-depth review of the safety data confirms no other safety signals and reinforces the strong safety profile of PulmoStem.

The study patients were followed for 22 days after administration of PulmoStem. At Day 22, all 6 patients were alive, i.e. 100% survival rate and no pre-defined study events had occurred. The median time until discharge from the hospital following PulmoStem administration was 6.5 days. One subgroup of patients with high baseline inflammation, assessed by the clinically used biomarker procalcitonin, displayed better clinical response and shorter time to hospital discharge.

- The confirmation of the safety profile and event-free survival will be a cornerstone for further development of PulmoStem in lung transplantation and for our other closely related cell therapeutic candidates, says Marcus Larsson, Amniotics’ CEO.

The full analysis of the biomarker data will guide the ongoing PulmoStem development. The work to finalise the full Clinical Study Report (CSR) is ongoing and is expected to be completed during quarter 3, 2023.